This ADC product is comprised of an anti-CD70 monoclonal antibody conjugated via a VC linker to a rachelmycin. The rachelmycin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within t
* VAT and and shipping costs not included. Errors and price changes excepted